involvement with HD occurs in only a minority of patients and that this tumor retains some degree of chemosensitivity after relapses, make HD an attractive disease in which to utilize high-dose therapy with stem cell rescue when conventional therapy fails to maintain complete remission. Although experience in children is limited, high-dose therapy with stem cell rescue has been shown to be superior to conventional treatment as second-line therapy, mainly in early relapses.
involvement with HD occurs in only a minority of patients and that this tumor retains some degree of chemosensitivity after relapses, make HD an attractive disease in which to utilize high-dose therapy with stem cell rescue when conventional therapy fails to maintain complete remission. Although experience in children is limited, high-dose therapy with stem cell rescue has been shown to be superior to conventional treatment as second-line therapy, mainly in early relapses. [1] [2] [3] [4] [5] [6] This retrospective study was undertaken to assess the outcome of children with HD undergoing progenitor cell transplant in eight hospitals in our country.
Patients and methods
We retrospectively reviewed the clinical records of 20 HD pediatric patients who underwent autologous stem-cell transplantation between October 1986 and September 1997 in eight hospitals belonging to the Spanish group for BMT in children (GETMON) .
Patient characteristics are shown in Table 1 . Sixteen patients had bulky mediastinal disease, seven extranodal disease (four with pulmonary parenchyma involvement) and eight 'B' symptoms, at the time of the initial diagnosis. First-line treatment and outcome prior to transplant are summarized in Table 2 . Six patients received multi-chemotherapy, mainly MOPP and ABVD and 14 combined modality therapy. Six out of these 14 patients were treated with OPPA plus COMP and involved field low-dose radiotherapy (20 Gy) according to our Spanish multi-center protocol of therapy. Three patients received low-dose radiotherapy (25 Gy) and five higher doses, ranging 30 to 44 Gy. Clinical status at transplant and conditioning regimen are shown in Table 3 . Only one patient, a 13-year-old boy with stage IV disease, bone marrow and lung involvement and B-symptoms at diagnosis, underwent transplant in first complete remission after six courses of conventional chemotherapy (MOPP three courses and ABVD three courses). Most of the patients underwent transplant in second complete remission. Relapse after first-line therapy occurred at a median of 16 months and median interval between first relapse and transplant was 7 months (range: 3-30 months). All except two patients received chemotherapy-based conditioning regimens, CBV being the most frequently used (55% of cases). Seven patients were supported with bone marrow stem cells, one patient with both bone marrow and peripheral blood, and the remaining 12 patients (63%) with peripheral blood only. After transplant, 16 patients received hematopoietic growth factors (G-CSF).
Engraftment was considered to have occurred when more than 1.0 × 10 9 /l WBC and Ͼ20 × 10 9 /l platelets without transfusion support were reached for 3 consecutive days.
Statistical analysis
Disease-free survival (DFS) was the primary end-point in this analysis. Survival time was calculated from the day of progenitor cells infusion (day 0). Survival rates were obtained by using the Kaplan and Meier method with 95% confidence interval derived from the standard errors. In DFS curves, censored observations reflect patients alive and in complete remission. Patients who relapsed or died in complete remission were considered failures.
Results

Hematopoietic recovery
All patients engrafted and recovery was faster after PBSCT. Median time to reach WBC Ͼ1.0 × 10 9 /l and PLT Ͼ20 × 10 9 /l was 13 and 16 days, respectively, after PB vs 16 and 39 days after bone marrow, in patients supported with G-CSF post transplant (Table 4) . A significant delay in platelet recovery was observed in two patients, both after ABMT.
Toxicity and early adverse events
Only one patient died as a result of transplant morbidity (sepsis and multiorganic failure).
Five patients had infectious complications: three had septicemia (Streptococcus viridans, Klebsiella) and two had pneumonia, which resolved uneventfully on antibiotics.
One patient developed hemolytic anemia and one patient had clinical evidence of mild veno-occlusive disease with resolution.
No other serious post-transplant morbid complications were found.
Response to transplant and overall outcome
Two patients transplanted in partial remission and two patients in sensitive relapse achieved complete remission 16 and 70 months after the previous one, with early and full engraftment and without transplant-related morbidity. One has remained in complete remission for 21 months, and the second one suffered from a further relapse and died 39 months after the second transplant. The three remaining patients who relapsed are alive, one in complete remission after salvage therapy without stem cell support.
At the time of data analysis, 18 children remain alive with a median follow-up time of 40 months (range, 6 to 127 months); 14 patients had no evidence of disease after stem-cell transplantation. A Kaplan-Meier plot of overall survival and DFS is shown in Figure 1 . The cumulative probability of 5-year overall survival (OS) was 0.95 and the projected probability of 5-year EFS was 0.62 for the entire group of patients. No statistical difference in projected EFS was found between patients undergoing transplant in second complete remission and patients transplanted in further complete remissions, relapse or partial remission (P = 0.7).
To date, none of the survivors has developed a second cancer.
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Discussion
The use of autologous stem cell transplantation (ASCT) for patients with HD who relapse after primary treatment has been widely investigated in adults but experience in children is scarce. On the other hand, there is a trend today to introduce megatherapy with ASCT as first-line treatment in adults with poor prognosis HD. [7] [8] [9] [10] A high percentage of children can be cured after conventional treatment, even those with advanced disease at diagnosis, 11, 12 so that, ASCT is not being used as part of front-line therapy in childhood. Nevertheless, the prognosis of children who fail to attain complete remission or who relapse after conventional treatment is poor, particularly if relapse occurs after a short complete remission. 13 High-dose chemotherapy with stem cell rescue is considered a possible therapeutic option to cure some of these patients.
We report a series of 20 children with HD who have undergone ASCT at different hospitals in our country. With the exception of one case transplanted in first remission, all patients underwent transplant after relapse. The first-line treatment was not uniform, but the majority of patients had been treated with combination chemotherapy and the addition of low-dose radiotherapy. The source of stem cells was bone marrow or peripheral blood according to the policy of each hospital. Although 14 children had received radiotherapy in the initial treatment, all patients scheduled to PB transplant were successfully mobilized and all of them engrafted.
The importance of pre-transplant cyto-reduction has been emphasised by several investigators. 6, 14, 15 In the current series of patients, high-dose therapy with stem cell rescue was useful for patients who did not achieve complete remission after conventional therapy. Both patients transplanted in partial remission and those transplanted in relapse, attained CR. Baker et al 16 have just reported nine children who underwent transplantation in untreated first relapse with a failure-free survival of 44% at 5 years. Nevertheless, the same authors found a dismal outcome for children transplanted in partial remission or with resistant relapse. We did not find a significant difference in EFS rates according to disease status at the time of ASCT, probably because of the small size of this group, since status at transplantation has been proven to be a significant prognostic factor in larger series of adult patients. 6, 14, 15, 17 No randomized studies comparing the effectiveness of ASCT vs standard chemotherapy in relapsed children with HD have been reported. Despite the fact that the follow-up time in our series of patients is not yet very long, the overall outcome is encouraging with an overall survival of 0.95 and EFS rate of 0.62.
Long-term toxicity is a very important subject in children with HD. The risk of developing a second cancer is well known. Sankila et al 18 reported an overall cumulative risk of subsequent malignancies of 18% at 30 years after conventional therapy in 1641 HD patients diagnosed during childhood and adolescence. Wolden et al 19 found an actuarial risk of developing a second cancer, at 20 years of follow-up, of 16.8 for females and 9.7 for males among 674 pediatric HD survivors at Stanford. The authors also found that relapse of HD significantly increased the risk of a second malignancy. Moreover, an increased incidence of second malignancies has also been reported after high-dose therapy, but it has been postulated that pretransplant chemotherapy itself may possibly play a role in causing this complication. 20, 21 High-dose therapy with ASCT early after second complete remission or in first relapse of HD could avoid high cumulative doses of some carcinogenic drugs and salvage radiation, but to date, it has not been possible to know whether the risk of second cancer can be reduced.
We conclude that high-dose therapy with stem cell rescue is feasible, with low early toxicity and that it can result in durable remissions and should be considered for children with advanced HD. Long-term survivors must continue to be closely followed.
